SCHEMBL2679308

SCHEMBL2679308

Cc1ccc(NC(=O)c2ccc(C)c(NC(=O)C=Cc3cncnc3)c2)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
TP53 P04637 2/20 0.49
NAMPT P43490 1/20 0.48
LCK P06239 1/20 0.48
KIT P10721 1/20 0.48
SRC P12931 1/20 0.48
MAPK14 Q16539 1/20 0.48
NPC1 O15118 7/20 0.48
THRB P10828 1/20 0.48
RAB9A P51151 5/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
CASP3 P42574 2/20 0.47
SENP7 Q9BQF6 2/20 0.47
SENP6 Q9GZR1 1/20 0.47
BRAF P15056 2/20 0.46
POLB P06746 2/20 0.44
EGFR P00533 1/20 0.44
CSF1R P07333 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10054898 0.96 NPC1 (0.51) MAPTSMN1; SMN2TP53NAMPTLCK
SCHEMBL10078767 0.95 MAPT (0.49) MAPTSMN1; SMN2TP53NAMPTLCK
SCHEMBL2679844 0.95 MAPT (0.49) MAPTSMN1; SMN2TP53NAMPTLCK
SCHEMBL10077760 0.92 LCK (0.48) MAPTSMN1; SMN2TP53LCKKIT
SCHEMBL2678790 0.92 LCK (0.48) MAPTSMN1; SMN2TP53LCKKIT
SCHEMBL10077696 0.89 LMNA (0.49) MAPTSMN1; SMN2TP53NAMPTLCK
SCHEMBL2679606 0.89 LMNA (0.49) MAPTSMN1; SMN2TP53NAMPTLCK
SCHEMBL2679066 0.88 BRAF (0.55) LCKKITSRCMAPK14BRAF
SCHEMBL10078411 0.88 BRAF (0.55) LCKKITSRCMAPK14BRAF
SCHEMBL2680451 0.88 LCK (0.48) MAPTSMN1; SMN2TP53NAMPTLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US claimed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US claimed
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US disclosed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament ABL1, ABL2, BCR MAPT 1476/4885SMN1; SMN2 4655/4885TP53 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.